This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, M. H. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Cohen, M. H. Articles by Pazdur, R.

Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia

Divisions Oncology Drug Products (HFD-150) [M. H. C., G. W., J. R. J., J. D., J. G., A. R., K. B., J. L., S. K. K., R. W., M. R., G. C., A. M. S., R. P.] and Scientific Investigations (HFD-45) [K. M. U.], Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857

ABSTRACT

Purpose: Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis. Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines. In this report, we describe the preclinical profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.

Experimental Design: Chemistry manufacturing and controls, animal toxicology, and biopharmaceutical data are described. Results of Phase I and Phase II clinical studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN- (CML-CP) are summarized. The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.

Results: Toxicology studies in the rat, dog, and monkey show the hematological, renal, and hepatobiliary toxicity of imatinib. Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability. The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approximately 18 and 40 h, respectively. Approximately 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine. Cytochrome P-450 3A4 is the main enzyme responsible for imatinib metabolism. Phase I and II clinical studies were conducted. The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day. Dose-limiting toxicity was not observed. The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients. CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day imatinib. Primary study endpoints were cytogenetic response rate (CML-CP) and hematological response rate (CML-AP and CML-BC). The cytogenetic response rate for CML-CP patients was 49%. The hematological response rate of CML-AP and CML-BC patients was 63 and 26%, respectively. The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea. Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).

Conclusions: On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufactured and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clinical settings: CML-BC, CML-AP, and CML-CP. This report summarizes the Food and Drug Administration’s review of the New Drug Application.

This article has been cited by other articles:

				S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors Toxicol Pathol, December 1, 2008; 36(7): 905 - 916. [Abstract] [Full Text] [PDF]

				H. Brenner, A. Gondos, and D. Pulte Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level Haematologica, October 1, 2008; 93(10): 1544 - 1549. [Abstract] [Full Text] [PDF]

				R. Capdeville, T. Krahnke, A. Hatfield, J. M. Ford, I. Van Hoomissen, and I. Gathmann Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias Ann. Onc., July 1, 2008; 19(7): 1320 - 1326. [Abstract] [Full Text] [PDF]

				J. R Foringer, R. R Verani, V. M Tjia, K. W Finkel, J. A Samuels, and J. S Guntupalli Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer Ann. Pharmacother., December 1, 2005; 39(12): 2136 - 2138. [Abstract] [Full Text] [PDF]

				B. Freidlin and R. Simon Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients Clin. Cancer Res., November 1, 2005; 11(21): 7872 - 7878. [Abstract] [Full Text] [PDF]

				B. Freidlin and R. Simon Evaluation of Randomized Discontinuation Design J. Clin. Oncol., August 1, 2005; 23(22): 5094 - 5098. [Abstract] [Full Text] [PDF]

				W. Slichenmyer Clinical Trial Strategies to Facilitate the Transition to Registration-Directed Trials Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 297 - 302. [Full Text] [PDF]

				M. H. Cohen, J. R. Johnson, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval Clin. Cancer Res., January 1, 2005; 11(1): 12 - 19. [Abstract] [Full Text] [PDF]

				R. Dagher, J. Johnson, G. Williams, P. Keegan, and R. Pazdur Accelerated Approval of Oncology Products: A Decade of Experience J Natl Cancer Inst, October 20, 2004; 96(20): 1500 - 1509. [Abstract] [Full Text] [PDF]

				P. F. Smith, J. M. Bullock, B. M. Booker, C. E. Haas, C. S. Berenson, and W. J. Jusko Induction of imatinib metabolism by hypericum perforatum Blood, August 15, 2004; 104(4): 1229 - 1230. [Full Text] [PDF]

				J. H. Schiller Clinical Trial Design Issues in the Era of Targeted Therapies Clin. Cancer Res., June 15, 2004; 10(12): 4281S - 4282S. [Abstract] [Full Text] [PDF]

				F. Guilhot Indications for Imatinib Mesylate Therapy and Clinical Management Oncologist, June 1, 2004; 9(3): 271 - 281. [Abstract] [Full Text] [PDF]

				K. Neville, R. A. Parise, P. Thompson, A. Aleksic, M. J. Egorin, F. M. Balis, L. McGuffey, C. McCully, S. L. Berg, and S. M. Blaney Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates Clin. Cancer Res., April 1, 2004; 10(7): 2525 - 2529. [Abstract] [Full Text] [PDF]

				G. Kramer, H. Erdal, H. J. M. M. Mertens, M. Nap, J. Mauermann, G. Steiner, M. Marberger, K. Biven, M. C. Shoshan, and S. Linder Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 Cancer Res., March 1, 2004; 64(5): 1751 - 1756. [Abstract] [Full Text] [PDF]

				G R Laking and P M Price Positron emission tomographic imaging of angiogenesis and vascular function Br. J. Radiol., December 1, 2003; 76(suppl_1): S50 - S59. [Abstract] [Full Text] [PDF]

				T. G. Roberts Jr, T. J. Lynch Jr, and B. A. Chabner The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision J. Clin. Oncol., October 1, 2003; 21(19): 3683 - 3695. [Abstract] [Full Text] [PDF]

				S. N. Gardner and M. Fernandes New tools for cancer chemotherapy: computational assistance for tailoring treatments Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084. [Abstract] [Full Text]

				J. R. Johnson, P. Bross, M. Cohen, M. Rothmann, G. Chen, A. Zajicek, J. Gobburu, A. Rahman, A. Staten, and R. Pazdur Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome-positive Chronic Myelogenous Leukemia in Chronic Phase Clin. Cancer Res., June 1, 2003; 9(6): 1972 - 1979. [Abstract] [Full Text] [PDF]